论文部分内容阅读
目的分析脑蛋白水解物治疗缺血性脑血管病的临床疗效及对神经功能的影响。方法在2015年12月至2016年10月到该院心血管科接受治疗的缺血性脑血管病患者中随机选择148例,根据治疗药物的差异,将入选患者分为对照组和观察组,各74例。对照组采取常规的药物进行处理,观察组利用脑蛋白水解物进行治疗,记录两组患者的治疗效果。结果对照组治疗总有效率[83.78%(62/74)]低于观察组[93.24%(69/74)],差异有统计学意义(P<0.05)。治疗后两组患者的神经功能缺损评分(NIHSS)与Barthel指数(BI)评分均较治疗前有明显改善,且治疗组显著优于对照组,差异均有统计学意义(P<0.05)。结论脑蛋白水解物治疗缺血性脑血管病的临床疗效比较明显,值得推广。
Objective To analyze the clinical efficacy of brain protein hydrolyzate in the treatment of ischemic cerebrovascular disease and its effect on neurological function. Methods From December 2015 to October 2016, 148 patients with ischemic cerebrovascular disease undergoing cardiovascular treatment in the hospital were randomly selected. According to the difference of the therapeutic drugs, the patients were divided into control group and observation group. 74 cases each. Control group to take conventional drugs for treatment, the observation group using brain protein hydrolysates for treatment, recording the treatment effect of two groups of patients. Results The total effective rate of the control group [83.78% (62/74)] was lower than that of the observation group [93.24% (69/74)], the difference was statistically significant (P <0.05). Neurological deficit scores (NIHSS) and Barthel index (BI) scores of the two groups after treatment were significantly improved than those before treatment, and the treatment group was significantly better than the control group, the difference was statistically significant (P <0.05). Conclusion The clinical efficacy of brain protein hydrolyzate in the treatment of ischemic cerebrovascular disease is obvious and worthy of promotion.